View Author
vaccine volunteer dose ama -1/as malaria study group immunization phase falciparum antigen trial blood parasite antibody challenge efficacy response control plasmodium malaria-na ıve adults period event parasitemia ama -1/as adult adjuvant protein safety inhibition immunogenicity growth prepatent period assay grade serum stage vaccine groups dose ama -1/ result wrair concentration prepatent sporozoite sample 1/2 system activity infectivity figure april apical membrane allele candidate analysis infectivity controls number elisa prepatent periods vaccination malaria challenge ifn-c light microscopy difference anti-ama www.plosone.org population volume issue state formulation 0.5 ml malaria vaccine -1/ malaria-na vaccinee sporozoite challenge plate ockenhouse cf merozoite
1 Most Recent Publications
|
Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-l) administered in adjuvant system AS01B or AS02A
(Article)
Spring, M.D. Cummings, J.F. Kortepeter, M.G. Nielsen, R. Krzych, U. Tierney, E. Ware, L.A. Dowler, M. Hermsen, C.C. Sauerwein, R.W. Vlas, S.J. de Ofori-Anyinam, O. Ockenhouse, C.F. Lanar, D.E. Williams, J.L. Kester, K.E. Tucker, K. Shi, M. Malkin, E. Long, C. Diggs, C.L. Soisson, L. Dubois, M.C. Dutta, S. Ballou, W.R. Cohen, J. Heppner J.r., D.G. Reidler, R. Angov, E. Bergmann-Leitner, E. Stewart, V.A. Bittner, S. Juompan, L. |
2009-04-23
|
